Furthermore, when examined in vivo, this medication had encouraging outcomes in a variety of mouse models, showing that targeting MYC in MM might be a feasible therapeutic approach that may help treat MM and other hematological malignancies [5]. This evidence concerns the gene MYC and Miyoshi myopathy.